Targeting NTPDase1/CD39, NT5E/CD73, adenosine or adenosine receptors is increasingly recognized as a promising intervention in anti-cancer therapy (Young et al., 2016; Allard et al., 2017). The gene discussed is NT5E; the disease is cancer.